CORRECTED-BRIEF- Eli Lilly and Co says EMPA-REG OUTCOME met its primary endpoint

Aug 20 (Reuters) - Eli Lilly and Co : * Jardiance demonstrated cardiovascular (cv) risk reduction in people with type 2 diabetes at high risk for cv events * Says empa-reg outcome met its primary endpoint * Says empa-reg outcome demonstrated superiority of jardiance, when added to standard of care, in cv risk reduction * Source text for Eikon * Further company coverage